ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Low 1-Year Venous Thromboembolic Recurrence Rates in Patients with and without Thrombotic Risk Factors in Routine Clinical Practice Treated with Edoxaban: The Global ETNA-VTE Study

A. Cohen1, C. Chen2, K.-M. Chiu3,4, W.-I. Choi5, M. Nakamura6, W. Zierhut7, P.-E. Reimitz8, M. Unverdorben2, G. Agnelli9

1Guy's and St Thomas' NHS Foundation Trust, King's College London, London, United Kingdom, 2Daiichi Sankyo, Inc., Global Medical Affairs, Basking Ridge, United States, 3Far Eastern Memorial Hospital, Cardiovascular Center, New Taipei City, Taiwan, Republic of China, 4Yuan Ze University, Electrical Engineering, Taoyuan City, Taiwan, Republic of China, 5Hanyang University Myongji Hospital, Department of Internal Medicine, Goyang-si, Korea, Republic of, 6Nakamura Medical Clinic, Department of Internal Medicine, Pediatrics and Cardiology, Kuwana, Japan, 7Daiichi Sankyo Europe GmbH, Medical Affairs Europe, Munich, Germany, 8Daiichi Sankyo Europe GmbH, Clinical Operations and Biostatistics and Data Operations, Munich, Germany, 9University of Perugia, Internal and Cardiovascular Medicine-Stroke Unit, Perugia, Italy

Abstract Number: PB/LB02

Meeting: ISTH 2020 Congress

Theme: Venous Thromboembolism and Cardioembolism » VTE Treatment

Background: The direct oral anticoagulant edoxaban was noninferior to conventional therapy with significantly less bleeding in patients with venous thromboembolism (VTE), including severe pulmonary embolism (PE). There is a paucity of contemporary baseline and outcome data comparing patients with and without VTE recurrence in the real-world clinical setting.

Aims: To analyze the impact of each individual provoked and unprovoked risk factor, including cancer, on VTE recurrence.

Methods: From eight European and three Asian countries, unselected acute symptomatic VTE patients treated with edoxaban participated in the non-interventional ETNA-VTE study and were followed for up to 12 months for safety and effectiveness.

Results: Of 4595 patients (48% male, mean age 64.9 years [SD 15.5]), 2666 (58%) were from Europe, 1652 (36%) from Japan, and 277 (6%) from South Korea and Taiwan. The vast majority of patients were on the recommended edoxaban doses of 60mg/30mg QD (4102/4595; 89%). VTE recurrence rates in Europe (68/2666; 2.6%), Japan (38/1652; 2.3%), and South Korea/Taiwan (10/277; 3.6%) were similar. The recurrence rate by index event, i.e., PE with/without DVT and DVT only were both 2.5%. Patients with VTE recurrence vs those without VTE recurrence were younger (62.7 [14.7] vs 65 [15.5] years), had the same VTE-BLEED score (median 1.5), had higher annualized event rates for all-cause mortality (11%/yr vs 5%/yr), major bleeding (5.6%/yr vs 2.4%/yr), and clinically relevant non-major bleeding (6.6%/yr vs 3.5%/yr).

Conclusions: The 12-month recurrence rate of VTE was low in patients receiving edoxaban, overall and by risk subgroups. In patients with active cancer and reversible provoked risk factors, VTE recurrence was more prevalent. Patients with VTE recurrence had higher annualized rates of bleeding events.

Baseline Characteristics All patients
[N=4595]
Without VTE recurrence
[N=4479]
With VTE recurrence
[N=116]
Body weight [kg], mean (SD) 72.8 (19.20) 72.8 (19.16) 75.5 (20.59)
Recalculated CrCl [mL/min], mean (SD) 87.9 (40.61) 87.7 (40.57) 96.9 (41.41)
Current smoker 551 (12%) 535 (12%) 16 (14%)
Active cancer 539 (12%) 519 (12%) 20 (17%)
Any reversible provoking risk factor* 992 (22%) 960 (21%) 32 (28%)
Thrombophilia** 92 (2.0%) 90 (2.0%) 2 (1.7%)
Unprovoked VTE 2981 (65%) 2919 (65%) 62 (53%)
History of VTE
History of major bleeding
793 (17%)
96 (2.1%)
775 (17%)
94 (2.1%)
18 (16%)
2 (1.7%)
All values are n (%) unless otherwise noted.
*Includes: major surgery or trauma, prolonged bed rest (5-7 days), and puerperium
**Includes: Antiphospholipid syndrome, deficiencies of protein C, protein S, and antithrombotic protein
All individual factors will be presented at the conference.

[Table 1. Baseline characteristics]


[Figure. VTE recurrence (%) by risk factor]

To cite this abstract in AMA style:

Cohen A, Chen C, Chiu K-, Choi W-, Nakamura M, Zierhut W, Reimitz P-, Unverdorben M, Agnelli G. Low 1-Year Venous Thromboembolic Recurrence Rates in Patients with and without Thrombotic Risk Factors in Routine Clinical Practice Treated with Edoxaban: The Global ETNA-VTE Study [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/low-1-year-venous-thromboembolic-recurrence-rates-in-patients-with-and-without-thrombotic-risk-factors-in-routine-clinical-practice-treated-with-edoxaban-the-global-etna-vte-study/. Accessed October 1, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/low-1-year-venous-thromboembolic-recurrence-rates-in-patients-with-and-without-thrombotic-risk-factors-in-routine-clinical-practice-treated-with-edoxaban-the-global-etna-vte-study/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress ยป

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley